Aleksandrs Zhavoronkov

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

Deep Longevity Ltd. develops artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system and psychological levels. Its products include longevity cloud, recommendation engines, deep aging clocks and age metric reports. The company was founded in 2020 by Alex Zhavoronkov and is headquartered in San Diego, CA.

Insilico Medicine IP Ltd. engages in the investment of drug discovery and drug development through the deployment of new artificial intelligence technologies. The company was founded on June 21, 2019 and is headquartered in Hong Kong.

The Alliance for Artificial Intelligence in Healthcare (AAIH) is an advocacy organization that aims to improve patient outcomes and minimize healthcare costs through the discovery, development, and delivery of better solutions. The private company is based in Long Island City, NY, and was founded by Brandon Allgood. The organization fosters creativity, collaboration, and knowledge sharing among its members, who come from diverse backgrounds in science, math, technology, and healthcare. AAIH is focusing on two primary practice areas in 2023: developing a comprehensive framework for digitizing IND and addressing core challenges in data accessibility through a real-world data registry.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland.

Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs.